Regulatory

Latest News

February 1st 2005

By Jill Wechsler, Pharm Exec’s Washington Correspondent

One response to today's safety concerns is particularly alarming: The research community has become skittish about conducting clinical studies involving pain medications and other high-risk treatments.

Trending on PharmExec

Regulatory

Latest News

Trending on PharmExec

Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro

Merck Planning $70 Billion Investment for US Expansion

FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps

Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings

Navigating the Complexities of a Global Pharma Expansion